Calithera Biosciences (CALA)

6.58 +0.15 (2.33%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (6/5/18 *Est.)

Latest Headlines

Form 4 Calithera Biosciences, For: Mar 11 Filed by: Orford Keith March 13, 2019 4:11 PM - SEC Filing Form S-8 Calithera Biosciences, March 7, 2019 4:52 PM - SEC Filing Form 10-K Calithera Biosciences, For: Dec 31 March 7, 2019 4:24 PM - SEC Filing Form 8-K Calithera Biosciences, For: Mar 07 March 7, 2019 4:08 PM - SEC Filing Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights March 7, 2019 4:06 PM - Globe NewsWire Calithera to Present at Cowen & Company 39th Annual Healthcare Conference March 5, 2019 7:05 AM - Globe NewsWire Calithera Biosciences to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019 March 4, 2019 7:05 AM - Globe NewsWire Calithera Biosciences Announces CB-708 Preclinical Data Presentation at the AACR Annual Meeting 2019 February 27, 2019 4:35 PM - Globe NewsWire Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference February 22, 2019 8:00 AM - Globe NewsWire Calithera Biosciences (CALA) Commences Phase 1 Trial of Arginase Inhibitor CB-280 for Treatment of Cystic Fibrosis February 21, 2019 4:57 PM - StreetInsider Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis February 21, 2019 4:05 PM - Globe NewsWire Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at 2019 ASCO Genitourinary Cancer Symposium February 16, 2019 6:00 AM - Globe NewsWire Form SC 13G/A Calithera Biosciences, Filed by: BIOTECHNOLOGY VALUE FUND L P February 14, 2019 4:41 PM - SEC Filing Form SC 13G Calithera Biosciences, Filed by: FEDERATED INVESTORS INC /PA/ February 13, 2019 3:11 PM - SEC Filing Form SC 13G/A Calithera Biosciences, Filed by: WELLINGTON MANAGEMENT GROUP LLP February 12, 2019 9:39 AM - SEC Filing Form 4 Calithera Biosciences, For: Feb 07 Filed by: Molineaux Christopher February 11, 2019 4:07 PM - SEC Filing Form 4 Calithera Biosciences, For: Feb 07 Filed by: Molineaux Susan February 11, 2019 4:07 PM - SEC Filing Form SC 13G/A Calithera Biosciences, Filed by: BlackRock Inc. February 4, 2019 10:08 AM - SEC Filing Calithera Biosciences (CALA) Reports Complete Patient Enrollment in Randomized Phase 2 ENTRATA Trial of Telaglenastat (CB-839) and Everolimus in Renal Cell Carcinoma February 4, 2019 7:20 AM - StreetInsider Calithera Biosciences Completes Patient Enrollment in Randomized Phase 2 ENTRATA Trial of Telaglenastat (CB-839) and Everolimus in Renal Cell Carcinoma February 4, 2019 7:05 AM - Globe NewsWire Form 4 Calithera Biosciences, For: Jan 10 Filed by: Molineaux Christopher January 14, 2019 4:39 PM - SEC Filing Form 4 Calithera Biosciences, For: Jan 10 Filed by: Sjogren Eric January 14, 2019 4:36 PM - SEC Filing Form 4 Calithera Biosciences, For: Jan 10 Filed by: Parlati Francesco January 14, 2019 4:35 PM - SEC Filing Form 4 Calithera Biosciences, For: Jan 10 Filed by: Molineaux Susan January 14, 2019 4:34 PM - SEC Filing Form 4 Calithera Biosciences, For: Jan 10 Filed by: Orford Keith January 14, 2019 4:33 PM - SEC Filing Form 4 Calithera Biosciences, For: Jan 10 Filed by: Hecht Curtis January 14, 2019 4:32 PM - SEC Filing Form 4 Calithera Biosciences, For: Jan 10 Filed by: Wong Stephanie January 14, 2019 4:31 PM - SEC Filing Form 4 Calithera Biosciences, For: Jan 10 Filed by: Ray Sumita January 14, 2019 4:30 PM - SEC Filing Form 8-K Calithera Biosciences, For: Jan 10 January 14, 2019 4:05 PM - SEC Filing Form 8-K Calithera Biosciences, For: Jan 07 January 7, 2019 4:04 PM - SEC Filing Calithera Biosciences Provides Corporate Updates and Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline January 7, 2019 7:05 AM - Globe NewsWire Full Article List